Compounds > desipramine

desipramine and vorinostat

desipramine has been researched along with vorinostat in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cardinaux, JR; Halfon, O; Magistretti, PJ; Meylan, EM1

Reviews

1 review(s) available for desipramine and vorinostat

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for desipramine and vorinostat

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: Possible relevance for treatment-resistant depression.
    Neuropharmacology, 2016, Volume: 107

    Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Desipramine; Disease Models, Animal; DNA-Binding Proteins; Drug Evaluation, Preclinical; Hippocampus; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Mice, Knockout; Nerve Tissue Proteins; Nuclear Receptor Subfamily 4, Group A, Member 1; Nuclear Receptor Subfamily 4, Group A, Member 2; Prefrontal Cortex; Receptors, Steroid; Receptors, Thyroid Hormone; Transcription Factors; Vorinostat

2016